Article

Daily aspirin linked to AMD risk

Data from a large European study link daily aspirin use to increased risk of age-related macular degeneration (AMD). Researchers found that people aged 65 and older who took aspirin daily had double the risk of developing wet AMD, compared with those who took it less frequently.

San Francisco-Data from a large European study link daily aspirin use to increased risk of age-related macular degeneration (AMD). Researchers found that people aged 65 and older who took aspirin daily had double the risk of developing wet AMD, compared with those who took it less frequently.

The study is published in the January issue of Ophthalmology.

Researchers also found a somewhat elevated risk of early-stage AMD in daily aspirin users, but no higher risk was found for advanced dry AMD.

Since many physicians recommend daily aspirin to patients with cardiovascular disease, researchers carefully analyzed whether participants’ heart health affected the study’s outcomes. But even when cardiovascular status was factored in, the results showed higher risk for wet AMD in patients who used aspirin daily. 

The researchers say medical professionals should stick with their current advice on aspirin for older patients with cardiovascular disease until other studies confirm the link between daily aspirin use and wet AMD risk. This research was part of the European Eye Study that examined more than 4,600 Europeans between 2000 and 2003.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.